DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 19.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 300,074 shares of the biopharmaceutical company’s stock after selling 73,686 shares during the quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main’s holdings in Gilead Sciences were worth $27,718,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of GILD. Bridgewater Associates LP raised its position in Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company’s stock valued at $42,577,000 after purchasing an additional 253,994 shares in the last quarter. McAdam LLC grew its holdings in Gilead Sciences by 16.7% during the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock worth $2,344,000 after acquiring an additional 3,627 shares in the last quarter. Capital Investment Advisors LLC increased its position in Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after purchasing an additional 9,791 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in shares of Gilead Sciences by 3.9% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company’s stock valued at $13,132,000 after purchasing an additional 5,382 shares in the last quarter. Finally, Global Financial Private Client LLC lifted its position in shares of Gilead Sciences by 1,222.0% in the 4th quarter. Global Financial Private Client LLC now owns 6,068 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 5,609 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $98.16 on Friday. The firm’s fifty day moving average is $107.59 and its two-hundred day moving average is $99.17. The firm has a market cap of $122.23 billion, a price-to-earnings ratio of 265.30, a PEG ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period last year, the company earned ($1.32) earnings per share. Gilead Sciences’s revenue for the quarter was down .3% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 3.22%. Gilead Sciences’s dividend payout ratio is presently 66.53%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GILD. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. The Goldman Sachs Group boosted their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Morgan Stanley raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a report on Thursday, February 13th. Finally, Oppenheimer cut their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.55.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at $17,597,559.49. This represents a 1.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last quarter, insiders sold 160,605 shares of company stock valued at $16,718,136. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.